Risk Factors
424 articles
COMBATing Pancreatic Cancer
Dr. Manuel Hidalgo explains the COMBAT trial, which combines immunotherapy, a checkpoint inhibitor, and chemotherapy to attack pancreatic cancer.
NALIRIFOX Shows Promise in Early Studies
Dr. Zev Wainberg describes the new combination NALIRIFOX, being tested in the NAPOLI-3 clinical trial for advanced pancreatic cancer patients.
Shedding More Light On Neoadjuvant Treatment
Dr. Matthew Katz reviews the study that compared neoadjuvant treatment with FOLFIRINOX versus gemcitabine/nab-paclitaxel for resectable pancreatic cancer.
AACR Virtual Special Conference on Pancreatic Cancer: Day One Highlights
Let’s Win and the Lustgarten Foundation present highlights of Day One of the AACR Virtual Special Conference on Pancreatic Cancer.
An Interview with Dr. Tyler Jacks
Dr. Tyler Jacks is one of the leading pancreatic cancer researchers. Read what he has to say about KRAS, organoids, and running a lab in a pandemic.
Tumor Subtypes Potentially Provide Clues About Prognosis and Treatment
Drs. Andrew Aguirre and David Ting are teasing out the differences between pancreatic cancer subtypes, to get treatments that work better.
Multi-Site Precision Promise Study Opens
Dr. Vincent Picozzi explains how Precision Promise clinical trial will use a personalized approach for pancreatic cancer patients.
Tweeting About Tumors and How Best to Provide Care
Dr. Michael Pishvaian launches #TumorBoardTuesday, a continuing medical education Twitter chat, to discuss patient treatments for GI cancers.
RNA Precision Trial for Pancreatic Cancer Opens At Columbia
Dr. Andrea Califano leads a precision oncology clinical trial of the OncoTreat platform, which looks at proteins to determine treatment.
Diversity Lacking in Pancreatic Cancer Trials
Drs. Kelly Herremans and Jose Trevino report on the lack of diversity in pancreatic cancer clinical trials, and possible root causes.
Large Phase III Global Trial Targets Cancer Metabolism
Dr. Philip Philip focuses on disrupting cancer cell metabolism with devimistat, now in a phase III global clinical trial.
The American Association for Cancer Research (AACR) Virtual Special Conference: Pancreatic Cancer Day One
Let’s Win and the Lustgarten Foundation present highlights of Day One of the AACR Virtual Special Conference on Pancreatic Cancer.
Triple Immunotherapy Shows Dramatic Results
Dr. William Freed-Pastor is testing a combination of three types of immunotherapy to attack pancreatic tumors.
New Clinical Accelerator Initiative Shortens Time from Bench to Clinic
Dr. Elizabeth Jaffee explains the importance of Lustgarten’s Clinical Accelerator Initiative to speed up the time from bench to trial.
PanCAN 2021 Annual Scientific Summit
Pancreatic Cancer Action Network (PanCAN) held its annual scientific summit for an overview of the latest research projects they are funding.